Skip to content

The hidden atherogenic burden of lipoprotein(a): Reclassification by risk-weighted apoB in a multicenter registry.

Aug 2026 · Atherosclerosis · Vol 421, pp. 121880 · 0 citations · 14 references
Medicine

TL;DR

Conventional apoB substantially underestimated weighted atherogenic burden in individuals with elevated Lp(a), with discordance increasing at higher concentrations, and particle-specific weighting approaches for apoB-based cardiovascular risk assessment are supported.

Abstract

Background

AND

Aims

Apolipoprotein B (apoB) is the preferred marker of atherogenic particle burden, but it assumes that all apoB-containing lipoproteins confer the same cardiovascular risk. Mendelian randomization studies suggest that triglyceride-rich lipoproteins (TRLs) and lipoprotein(a) [Lp(a)] are more atherogenic per apoB particle than LDL. Risk-weighted apoB (RW-apoB) captures these differences in a single metric. We assessed the reclassification produced by RW-apoB versus measured apoB in the GAELp(a) registry, a real-world Lp(a)-enriched cohort.

Methods

This post-hoc analysis of the GAELp(a) registry included 1861 adults with available apoB, Lp(a) expressed in nmol/L, and fasting triglycerides (TG) < 250 mg/dL. RW-apoB was calculated as: 11.65 × TG (mmol/L) + 0.215 × Lp(a) (nmol/L) + 0.736 × apoB (mg/dL). Reclassification was defined as the change in percentile rank between RW-apoB and measured apoB (Δ percentile). Analyses were stratified across five Lp(a) categories. A complementary analysis without TG truncation was performed in 1966 participants to evaluate the contribution of each RW-apoB component.

Results

Mean apoB was 89.9 ± 27.6 mg/dL, whereas mean RW-apoB was 103.7 ± 36.3 mg/dL. Overall, 60.0% of participants were reclassified by ≥ 10 percentile points. In individuals with Lp(a) < 75 nmol/L, measured apoB slightly overestimated weighted atherogenic burden (median Δ percentile: -13.2). Conversely, apoB progressively underestimated weighted atherogenic burden with increasing Lp(a), reaching an RW-apoB/apoB ratio of 1.91 and median Δ percentile of +34.7 at Lp(a) ≥300 nmol/L. The reclassification pattern was virtually identical in the no-truncation analysis (60.0%), with Lp(a)-not TRL-identified as the primary driver of discordance between RW-apoB and measured apoB.

Conclusions

Conventional apoB substantially underestimated weighted atherogenic burden in individuals with elevated Lp(a), with discordance increasing at higher concentrations. These findings support particle-specific weighting approaches for apoB-based cardiovascular risk assessment.

View source

Similar papers

Oct 2026

A-030 LDL-C and Apolipoprotein B Concordance Across Different Thresholds: Impact of Hypertriglyceridemia in a Real-World Laboratory Cohort

Low-density lipoprotein cholesterol (LDL-C) remains the primary target for cardiovascular risk reduction; however, it reflects cholesterol content rather than the total number of circulating atherogenic particles. Apolipoprotein B (ApoB), present in one copy per atherogenic lipoprotein particle, more directly rep...

M. Bezerra, Alice Petrola Bezerra Sayao, Rachel Petrola et al. · 0 citations
Open access Sep 2026

Balance of non-Lp(a) apoB and Lp(a) with Coronary Plaque Phenotypes and MACE: Insights from PROSPECT II and CASABLANCA.

Differentiating Lp(a)-associated from non-Lp(a)-associated apoB particle pools provides complementary information on coronary plaque phenotype, and the non-Lp(a) apoB/Lp(a) ratio summarizes their relative predominance.

S. Tsimikas, J. Januzzi, Michael Maeng et al. · 0 citations
Review Open access Sep 2026

Clinical utility of lipoprotein(a) and the ApoB/ApoA-I ratio in the risk assessment of acute coronary syndrome: from single biomarkers to integrated risk stratification

Acute coronary syndrome (ACS) is a critical clinical emergency resulting from the rupture or erosion of coronary atherosclerotic plaques and subsequent thrombosis. Its pathogenesis is driven by a complex interplay of dysregulated lipid metabolism, inflammatory responses, thrombotic processes, and genetic susceptibility...

Zu-Qiang Lu, Pan-Kui Li, Rui-Rui Li et al. · 0 citations
Review Open access Sep 2026

Apolipoprotein B in cardiovascular risk assessment: beyond traditional lipid markers

Apolipoprotein B (ApoB) serves as the structural backbone of triglyceride (TG)-rich lipoproteins and low-density lipoprotein (LDL) particles and plays a key role in lipid transport. A growing body of evidence indicates that circulating ApoB levels are closely associated with the development of cardiovascular diseases s...

Ling-Ling Li, Yi-Xuan Feng, Xiao-Ya Li et al. · 0 citations
Open access Sep 2026

Associations of apolipoprotein A1, apolipoprotein B, and their ratio with novel cardiometabolic indices in adults with coronary artery disease

Background Circulating apolipoprotein A1 (ApoA1) and apolipoprotein B (ApoB) have been proposed as vital biomarkers in the pathological process of coronary heart disease (CAD). However, their associations with novel cardiometabolic indices [triglyceride glucose body mass index (TyG-BMI), atherogenic index of plasma (AI...

Ping Hu, Nan Lu, Jie Wang et al. · 0 citations
Open access Sep 2026

Lipoprotein (a) variability in high cardiovascular risk individuals with hypertriglyceridemia and controlled LDL-C on statin therapy in REDUCE-IT.

Findings suggest multiple assessments may be warranted for Lp(a)-related risk stratification and, potentially, eligibility for Lp(a)-targeted treatments, particularly among individuals with relatively high concentrations or certain demographic and clinical characteristics.

M. Szarek, Deepak L. Bhatt, Michael Miller et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.